Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

$CDTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $CDTX alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $CDTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CDTX

DatePrice TargetRatingAnalyst
3/12/2025$46.00Mkt Outperform
Citizens JMP
1/27/2025Overweight
Cantor Fitzgerald
12/13/2024$34.00Outperform
RBC Capital Mkts
11/8/2024$33.00Buy
Guggenheim
8/14/2024$24.00Neutral → Buy
H.C. Wainwright
12/3/2021$6.00Buy
H.C. Wainwright
9/22/2021$9.00 → $8.00Buy
Aegis Capital
9/22/2021$6.25Buy → Strong Buy
WBB Securities
More analyst ratings

$CDTX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

    SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that the Compensation and Human Capital Committee of its Board of Directors (Compensation Committee) granted Timothy Alefantis, a new employee, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 27,000 shares of its common stock, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the Inducement Plan), with a grant date of March 31, 2025. The stock option has an exercise price of $21.54 per share, whi

    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

    SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that company management will participate in the 24th Annual Needham Virtual Healthcare Conference. Details are as follows: Event: 24th Annual Needham Virtual Healthcare ConferenceDate: Wednesday, April 9, 2025Time: 11:00 AM ET Format: Presentation Webcast: https://wsw.com/webcast/needham146/cdtx/2261559 A replay of the presentation will be available in the Investors section on the Company's website at www.cidara.com. The replay of the presentation will be available for

    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response

    SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced participation in the "Other pharmaceuticals as preventive tools" panel at a World Health Organization (WHO) global meeting on H5N1 influenza preparedness and response. The meeting, titled "What research is important to prepare and respond to H5N1 influenza outbreaks," will be held virtually on March 19, 2025, from 1:00-7:15pm Central European Time (CET)/5:00-11:15am Pacific Time (PT), and the panel discussion will take place from 6:30-7:00 pm CET/10:30-11:00am PT. "Globa

    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$CDTX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CDTX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$CDTX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CDTX
SEC Filings

See more

$CDTX
Leadership Updates

Live Leadership Updates

See more
  • Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

    Completed enrollment of 5,000 subject Phase 2b NAVIGATE trialSevere flu season enables potential mid-year assessment of efficacyClosed $105.0 million financing with new and existing investorsSignificantly expanded equity research coverage SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business updates. "2024 was a transformational year for Cidara as we reacquired rights to the CD388 program

    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer

    SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Frank Karbe, MBA, has been appointed Chief Financial Officer (CFO), effective February 24, 2025. Mr. Karbe will succeed Preetam Shah, Ph.D., MBA, who is departing to pursue other professional opportunities. Dr. Shah will serve as a consultant to the Company. "We are pleased to welcome Frank to the team as we advance our long-acting influenza antiviral drug CD388 through the e

    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts

    SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the appointment of Rick Bright, Ph.D., Philip Krause, M.D., Mario Barro, Ph.D., and Frederick G. Hayden, M.D., FACP to its Scientific Advisory Board (SAB). "We are honored that these four esteemed physicians and scientists have agreed to join our Scientific Advisory Board," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "They have already provided i

    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$CDTX
Financials

Live finance-specific insights

See more
  • Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million

    - $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial - CD388, which is active against all strains of influenza A and B, is being developed for pre-exposure prophylactic treatment - Company to host business strategy update conference call and webcast today at 4:30 PM ET SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve

    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.

    Submitted NDA for rezafungin for candidemia and invasive candidiasis to the U.S. FDA on July 22, 2022, with an anticipated PDUFA target action date in the first quarter of 2023, if accepted for review following application validationMelinta acquires exclusive rights to commercialize rezafungin in the U.S.Cidara to receive up to $460 million, with an upfront cash payment of $30 million, $60 million in regulatory milestones, and up to $370 million in commercial milestones, plus tiered low double digits to mid-teens royalties on net salesCidara to focus on advancing Cloudbreak DFC platform in oncology and viral infections SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc

    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

    Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care Data to support global regulatory filings in mid-2022 Cidara to host investor conference call today, December 14th, at 8:30 a.m. EST to provide further details on the data SAN DIEGO and CAMBRIDGE, United Kingdom, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) and Mundipharma today announced positive topline data from the pivotal ReSTORE Phase 3 clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential first-line treatment for candidemia and invasive candidiasis. Rezafungin met the primary endpoint for the U.S. Food and

    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$CDTX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more